Developments and future trends in anticancer natural products drug discovery

Anticancer Agents from Natural Products

Volumn , Issue , 2005, Pages 553-572

  Newman, David J ^a   Cragg, Gordon M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-CANCER AGENTS; ANTI-TUMOR AGENTS; CHEMOTYPES; CLINICAL USE; DRUG DISCOVERY; FUTURE TRENDS; NATURAL PRODUCTS;

DRUG PRODUCTS;

EID: 33646071153     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (87)

1. Newman, D. J., Cragg, G. M., and Snader, K. M., Natural products as sources of new drugs over the period 1981-2002, J. Nat. Prod., 66, 1022, 2003.
2. Cragg, G. M. and Newman, D. J., A tale of two tumor targets: Topoisomerase I and tubulin. The Wall and Wani contribution to cancer chemotherapy, J. Nat. Prod., 67, 232, 2004.
3. Sielecki, T. et al., Cyclin-dependent kinase inhibitors: Useful targets in cell cycle regulation, J. Med. Chem., 43, 1, 2000.
4. Losiewicz, M. D. et al., Potent inhibition of cdc2 kinase activity by the flavanoid, l86-8275, Biochem. Biophys. Res. Comm., 201, 589, 1994.
5. Czech, J. et al., Anti-tumoral activity of flavone l 86-8275, Int. J. Oncol., 6, 31, 1995.
6. Dai, Y. and Grant, S., Cyclin-dependent kinase inhibitors, Curr. Opin. Pharmacol., 3, 362, 2003.
7. Dancey, J. and Sausville, E. A., Issues and progress with protein kinase inhibitors for cancer treatment, Nature Rev. Drug Disc., 2, 296, 2003.
8. Senderowicz, A. M., Small-molecule cyclin-dependent kinase modulators, Oncogene, 22, 6609, 2003.
9. Meijer, L. and Raymond, E., Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials, Acc. Chem. Res., 36, 417, 2003.
10. Parker, C. W., Entsch, B., and Letham, D., Inhibitors of two enzymes which metabolize cytokinins, Phytochemistry, 25, 303, 1986.
11. Chang, Y. T. et al., Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors, Chem. Biol., 6, 361, 1999.
12. Evans, B. E. et al., Methods for drug discovery: Development of potent, selective, orally effective cholecystokinin antagonists, J. Med. Chem., 31, 2235, 1988.
13. Mason, J. S. et al., New 4-point pharmacophore method for molecular similarity and diversity applications: Overview of the method and applications, including a novel approach to the design of combinatorial libraries containing privileged sub-structures, J. Med. Chem., 42, 3251, 1999.
14. Patchett, A. A. and Nargund, R. P., Privileged structures — an update, in Ann. Repts. Med. Chem., Doherty, A. M., Ed., Academic Press, San Diego, CA, 2000, Vol. 35, pp 289–298.
15. Nicolaou, K. C. et al., Natural product-like combinatorial libraries based on privileged structures. 1. General principles and solid-phase synthesis of benzopyrans, J. Am. Chem. Soc., 122, 9939, 2000.
16. Nicolaou, K. C. et al., Natural product-like combinatorial libraries based on privileged structures. 2. Construction of a 10,000-membered benzopyran library by directed split-and-pool chemistry using nanokans and optical encoding, J. Am. Chem. Soc., 122, 9954, 2000.
17. Nicolaou, K. C. et al., Natural product-like combinatorial libraries based on privileged structures. 3. The “libraries from libraries” principle for diversity enhancement of bezopyran libraries, J. Am. Chem. Soc., 122, 9968, 2000.
18. Nicolaou, K. C. et al., Polymer-supported selenium reagents for organic synthesis, Chem. Comm., 1947, 1998.
19. Nicolaou, K. C. et al., Combinatorial synthesis of novel and potent inhibitors of NADH: Ubiquinone oxidoreductase, Chem. Biol., 7, 979, 2000.
20. Nicolaou, K. C. et al., Discovery of novel antibacterial agents active against methicillin-resistant Staphylococcus aureus from combinatorial benzopyran libraries, ChemBioChem, 460, 2001.
21. Nicolaou, K. C. et al., Discovery and optimization of non-steroidal FXR agonists from natural productlike libraries, Org. Biomol. Chem., 1, 908, 2003.
22. Downes, M. et al., A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR, Mol. Cell, 11, 1079, 2003.
23. Strobel, G. et al., Natural products from endophytic microorganisms, J. Nat. Prod., 67, 257, 2004.
24. Cuendet, M. and Pezzuto, J. M., Antitumor activity of bruceantin. An old drug with new promise, J. Nat. Prod., 67, 269, 2004.
25. Melichar, B. et al., Growth-inhibitory effect of a novel synthetic triterpenoid, 2-cyano-3,12-dioxoalean-1,9-dien-28-oic acid, on ovarian carcinoma cell lines not dependent on peroxisome proliferatorsactivated receptor-γ expression, Gynecol. Oncol., 93, 149, 2004.
26. Li, Y. et al., Selective killing of cancer cells by β-lapachone: Direct checkpoint activation as a strategy against cancer, Proc. Natl. Acad. Sci., USA, 100, 2674, 2003.
27. Choi, B. T., Cheong, J., and Choi, Y. H., β-lapachone-induced apoptosis is associated with activation of caspase-3 and inactivation of NF-κB in human colon cancer HCT-116 cells, Anti-Cancer Drugs, 14, 845, 2003.
28. Ravelo, A. G. et al., Recent studies on natural products as anticancer agents, Curr. Topics Med. Chem., 4, 241, 2004.
29. Scott, J. D. and Williams, R. M., Chemistry and biology of the tetrahydroisoquinoline antitumor antibiotics, Chem. Rev., 102, 1669, 2002.
30. Oku, N. et al., Renieramycin J, a highly cytotoxic tetrahydroisoquinoline alkaloid, from a marine sponge Neopetrosia sp., J. Nat. Prod., 66, 1136, 2003.
31. Fontana, A. et al., A new antitumor isoquinoline alkaloid from the marine nudibranch Jorunna funebris, Tetrahedron, 56, 7305, 2000.
32. Moss, C. et al., Intracellular bacteria associated with the ascidian Ecteinascidia turbinata: Phylogenetic and in situ hybridization analysis, Mar. Biol., 143, 99, 2003.
33. Zabriskie, T. M. et al., Jaspamide, a modified peptide from a Jaspis sponge, with insecticidal and antifungal activity, J. Am. Chem. Soc., 108, 3123, 1986.
34. Crews, P., Manes, L. V., and Boehler, M., Jasplakinolide, a cyclodepsipeptide from the marine sponge, Jaspis sp., Tetrahedron Lett., 27, 2797, 1986.
35. Zampella, A. et al., New jaspamide derivatives from the marine sponge Jaspis splendans collected in Vanuatu, J. Nat. Prod., 62, 332, 1999.
36. Bubb, M. R. et al., Jasplakinolide, a cytotoxic natural product, induces actin polymerization and competitively inhibits the binding of phalloidin to f-actin, J. Biol. Chem., 269, 14869, 1994.
37. Senderowicz, A. M. et al., Jasplakinolide’s inhibition of the growth of prostate carcinoma cells in vitro with disruption of the actin cytoskeleton, J. Nat. Can. Inst., 87, 46, 1995.
38. Chan, W. R. et al., Stereostructures of geodiamolides A and B, novel cyclodepsipeptides from the marine sponge Geodia sp., J. Org. Chem., 52, 3091, 1987.
39. Coleman, J. E., Van Soest, R. W. M., and Andersen, R. J., New geodiamolides from the sponge Cymbastela sp. collected in Papua New Guinea, J. Nat. Prod., 62, 1137, 1999.
40. Kunze, B. et al., Chondramides A-D, new antifungal and cytostatic depsipeptides from Chondromyces crocatus (myxobacteria). Production, physico-chemical and biological properties, J. Antibiotics, 48, 1262, 1995.
41. Sasse, F. et al., The chondramides: Cytostatic agents from myxobacteria acting on the actin cytoskeleton, J. Nat. Can. Inst., 90, 1559, 1998.
42. Perry, N. B. et al., Mycalamide A, an antiviral compound from a New Zealand sponge of the genus Mycale, J. Am. Chem. Soc., 110, 4850, 1988.
43. Pettit, G. R. et al., Antineoplastic agents. 520. Isolation and structure of irciniastatins A and B from the Indo-Pacific marine sponge Ircinia ramosa, J. Med. Chem., 47, 1149, 2004.
44. Cichewicz, R. H., Valeriote, F. A., and Crews, P., Psymberin, a potent sponge-derived cytotoxin from Psammocinia distantly related to the pederin family, Org. Lett., 6, 1951, 2004.
45. Trost, B. M., Yang, H., and Probst, G. D., A formal synthesis of (-)-mycalamide A, J. Am. Chem. Soc., 126, 48, 2004.
46. Kellner, R. L. L., Molecular identification of an endosymbiotic bacterium associated with pederin biosynthesis in Paederus sabaeus (coleoptera: Staphylinidae), Insect Biochem. Mol. Biol., 32, 389, 2002.
47. Piel, J., Hofer, I., and Hui, D., Evidence for a symbiosis island involved in horizontal acquisition of pederin biosynthetic capabilities by the bacterial symbiont of Paederus fuscipes beetles, J. Bact., 186, 1280, 2004.
48. Piel, J., A polyketide synthase-peptide synthase gene cluster from an uncultured bacterial symbiont of Paederus beetles, Proc. Natl. Acad. Sci. USA, 99, 14002, 2002.
49. Kasanah, N. et al., Biotransformation and biosynthetic studies of the manzamine alkaloids, Abs. Pap. 6th Int. Mar. Biotech. Conf., Abs S14, 2003.
50. Yousaf, M. et al., Solving limited supplies of marine pharmaceuticals through the rational and highthroughput modification of high yielding marine natural producer scaffolds, Abs. Pap. 6th Int. Mar. Biotech. Conf., Abs. S14, 2003.
51. Mincer, T. J. et al., Widespread and persistent populations of a major new marine actinomycete taxon in ocean sediments, Appl. Environ. Microbiol., 68, 5005, 2002.
52. Feling, R. H. et al., Salinosporamide A; a highly cytotoxic proteosome inhibitor from a novel microbial source, a marine bacterium of the new genus Salinospora, Angew. Chem. Int. Ed., 42, 355, 2003.
53. Omura, S. et al., Lactacystin, a novel microbial metabolite, induces neuritogenesis of neuroblastoma cells, J. Antibiot., 44, 113, 1991.
54. Corey, E. J. and Li, W. D., Total synthesis and biological activity of lactacystin, omuralide and analogs, Chem. Pharm. Bull., 47, 1, 1999.
55. Fenteany, G. et al., Inhibition of proteosome activities and subunit-specific amino-terminal threonine modification by lactacystin, Science, 268, 726, 1995.
56. Kisselev, A. F. and Goldberg, A. L., Proteosome inhibitors: From research tools to drug candidates, Chem. Biol., 8, 739, 2001.
57. Reddy, L. J., Saravanan, P., and Corey, E. J., A simple stereocontrolled synthesis of salinosporamide A, J. Am. Chem. Soc., 126, 6230, 2004.
58. Newman, D. J. and Cragg, G. M., Marine natural products and related compounds in clinical and advanced preclinical trials, J. Nat. Prod., 67, 1216, 2004.
59. Arabshahi, L. and Schmitz, F. J., Brominated tyrosine metabolites from an unidentified sponge, J. Org. Chem., 52, 3584, 1987.
60. Quinoa, E. and Crews, P., Phenolic constituents of Psammaplysilla, Tet. Lett., 28, 3229, 1987.
61. Pina, I. C. et al., Psammaplins from the sponge Pseudoceritina purpurea: Inhibition of both histone deacetylase and DNA methyltransferase, J. Org. Chem., 68, 3866, 2003.
62. Remiszewski, S. W. et al., N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: Discovery of (2e)-n-hydroxy-3-[4-[[2-hydroxyethyl[2-(1h-indol-3-yl)ethyl]aminomethyl]-phenyl]-2-propenamide (NVP-LAQ824), J. Med. Chem., 46, 4609, 2003.
63. Remiszewski, S. W., The discovery of NVP-LAQ824: From concept to clinic, Curr. Med. Chem., 10, 2393, 2003.
64. Catley, L. et al., NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma, Blood, 102, 2615, 2003.
65. Yoshida, M. et al., Effects of leptomycin B on the cell cycle of fibroblasts and fission yeast cells, Exp. Cell Res., 187, 150, 1990.
66. Nishi, K. et al., Leptomycin B targets a regulatory cascade of crm1, a fission yeast nuclear protein, involved in control of higher order chromosome structure and gene expression, J. Biol. Chem., 269, 6320, 1994.
67. Kudo, N. et al., Leptomycin B inhibition of signal-mediated nuclear export by direct binding to crm1, Exp. Cell Res., 242, 540, 1998.
68. Kudo, N. et al., Leptomycin B inactivates crm1/exportin 1 by covalent modification at a cysteine residue in the central conserved region, Proc. Natl. Acad. Sci., USA, 96, 9112, 1999.
69. Henderson, B. R. and Eleftheriou, A., A comparison of the activity, sequence specificity, and crm1-dependence of different nuclear export signals, Exp. Cell Res., 256, 213, 2000.
70. Vigneri, P. and Wang, J. Y. J., Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of bcr-abl tyrosine kinase, Nat. Med., 7, 228, 2001.
71. Yashiroda, Y. and Yoshida, M., Nucleo-cytoplasmic transport of proteins as a target for therapeutic drugs, Curr. Med. Chem., 10, 741, 2003.
72. Krohn, K. et al., Palmarumycins C1-C16 from Coniothyrium: Isolation, structure elucidation, and biological activity, Liebigs Ann. Chem., 1099, 1994.
73. Welsh, S. J. et al., The thioredoxin redox inhibitors 1-methylpropyl 2-imidazoyl disulfide and pleurotin inhibit hypoxia-induced factor 1-α and vascular endothelial growth factor formation, Mol. Can. Therap., 2, 235, 2003.
74. Wipf, P. et al., New inhibitors of the thioredoxin-thioredoxin reductase system based on a naphthaquinone spiroketal natural product lead, Bioorg. Med. Chem. Lett., 11, 2637, 2001.
75. Lazo, J. et al., Antimitotic actions of a novel analog of the fungal metabolite palmarumycin CP1, J. Pharmacol. Exp. Ther., 296, 364, 2001.
76. Wipf, P. et al., Natural product based inhibitors of the thioredoxin-thioredoxin reductase system, Org. Biomol. Chem., 2, 1651, 2004.
77. Maugard, T. et al., Identification of an indigo precursor from leaves of Isatis tinctoria (Woad), Phytochemistry, 58, 897, 2001.
78. Cooksey, C. J., Tyrian purple: 6,6′-dibromoindigo and related compounds, Molecules, 6, 736, 2001.
79. MacNeil, I. A. et al., Expression and isolation of antimicrobial small molecules from soil DNA libraries, J. Mol. Microbiol. Biotechnol., 3, 301, 2001.
80. Adachi, J. et al., Indirubin and indigo are potent aryl hydrocarbon receptor ligands present in human urine, J. Biol. Chem., 276, 31475, 2001.
81. Chen, D. and Xie, J., Chemical constituents of a traditional Chinese medicine Qing Dai, Zhongcaoyao, 15, 534, 1984.
82. Xiao, Z. et al., Indirubin and mesoindigo in the treatment of chronic myelogenous leukemia in China, Leuk. Lymphoma, 43, 1763, 2002.
83. Meijer, L. et al., GSK-3-selective inhibitors derived from Tyrian purple indirubins, Chem. Biol., 10, 1255, 2003.
84. Polychronopoulos, P. et al., Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases, J. Med. Chem., 47, 935, 2004.
85. Denison, M. S. and Nagy, S. R., Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals, Annu. Rev. Pharmacol. Toxicol., 43, 309, 2003.
86. Knockaert, M. et al., Independent actions on cyclin-dependent kinases and aryl hydrocarbon receptor mediates the antiproliferative effects of indirubins, Oncogene, 23, 4400, 2004.
87. Schloss, P. D. and Handelsman, J., Biotechnological prospects from metagenomics, Curr. Opin. Biotechnol., 14, 303, 2003.